Table 2.
Frequency of tissue-agnostic targets in different cancer types (alphabetically arranged) in AACR GENIE v13.
| Alteration frequency | |||||
|---|---|---|---|---|---|
| Cancer type | BRAF V600E | RET fusion | NTRK fusion | TMB-high (> 16) | TMB-high (≥ 10) |
| Ampullary cancer | 1.1% (n = 4) | 0% (n = 0) | 5.1% (n = 2) | 13% (n = 46) | 19.3% (n = 68) |
| Anal cancer | 0% (n = 0) | 2% (n = 1) | 2% (n = 1) | 12% (n = 44) | 19.9% (n = 73) |
| Appendiceal cancer | 1.2% (n = 9) | 0% (n = 0) | 2.1% (n = 1) | 14.6% (n = 108) | 18.5% (n = 137) |
| Bladder cancer | 0.1% (n = 6) | 0.3% (n = 3) | 1% (n = 9) | 20.3% (n = 947) | 38.8% (n = 1,813) |
| Breast cancer | 0.1% (n = 17) | 0.4% (n = 13) | 1.4% (n = 41) | 7.7% (n = 1,235) | 11.7% (n = 1,874) |
| Cancer of unknown primary | 1.6% (n = 86) | 1% (n = 8) | 1.5% (n = 12) | 15.2% (n = 815) | 23.4% (n = 1,249) |
| Cervical cancer | 0% (n = 0) | 0% (n = 0) | 0% (n = 0) | 11.5% (n = 100) | 18.2% (n = 158) |
| Colorectal cancer | 7.9% (n = 1,228) | 0.9% (n = 15) | 1.7% (n = 29) | 26.8% (n = 4,145) | 31.9% (n = 4,937) |
| Endometrial cancer | 0.1% (n = 4) | 0.1% (n = 1) | 0.5% (n = 4) | 24.7% (n = 1,257) | 30.4% (n = 1,549) |
| Esophagogastric cancer | 0.1% (n = 6) | 0.7% (n = 8) | 1.8% (n = 20) | 11.4% (n = 541) | 17.2% (n = 817) |
| Gastrointestinal neuroendocrine tumor | 3.7% (n = 25) | 0% (n = 0) | 5.4% (n = 3) | 4% (n = 27) | 6.6% (n = 45) |
| Gastrointestinal stromal tumor | 0.4% (n = 6) | 0% (n = 0) | 0.8% (n = 1) | 14.4% (n = 222) | 14.6% (n = 226) |
| Germ cell tumor | 0.1% (n = 1) | 0% (n = 0) | 1.1% (n = 1) | 2.2% (n = 23) | 2.9% (n = 31) |
| Glioma | 3.9% (n = 392) | 0.3% (n = 6) | 1.8% (n = 43) | 9.8% (n = 988) | 11.1% (n = 1,121) |
| Head and neck cancer | 0.05% (n = 1) | 0.8% (n = 2) | 0.8% (n = 2) | 15.6% (n = 344) | 24.9% (n = 548) |
| Hepatobiliary cancer | 1.1% (n = 39) | 0.5% (n = 3) | 1.6% (n = 10) | 8.4% (n = 291) | 12% (n = 413) |
| Histiocytosis | 17.3% (n = 91) | 8% (n = 2) | 0% (n = 0) | 2.7% (n = 14) | 2.7% (n = 14) |
| Hodgkin lymphoma | 0% (n = 0)a | 0% (n = 0) | 0% (n = 0) | 4.8% (n = 6) | 7.9% (n = 10) |
| Leukemia | 0.2% (n = 9) | 0% (n = 0) | 0% (n = 0) | 22.8% (n = 1,351) | 28% (n = 1,660) |
| Melanoma | 20.3% (n = 1,379) | 0.1% (n = 1) | 2.6% (n = 18) | 39.8% (n = 2,709) | 49.1% (n = 3,338) |
| Mesothelioma | 0.1% (n = 1) | 0% (n = 0) | 1% (n = 2) | 2% (n = 19) | 2.8% (n = 27) |
| Non-Hodgkin lymphoma | 1.6% (n = 1) | 0% (n = 0) | 0% (n = 0) | 8.1% (n = 5) | 9.7% (n = 6) |
| NSCLC | 1.4% (n = 329) | 5.7% (n = 215) | 0.9% (n = 33) | 22.6% (n = 5,447) | 33.8% (n = 8,142) |
| Ovarian cancer | 0.9% (n = 56) | 0% (n = 0) | 0.6% (n = 7) | 10.3% (n = 630) | 12.8% (n = 783) |
| Pancreatic cancer | 0.4% (n = 26) | 0.1% (n = 1) | 1.8% (n = 15) | 10.3% (n = 706) | 11.9% (n = 820) |
| Parathyroid cancer | 6.9% (n = 2) | 0% (n = 0)a | 0% (n = 0)a | 44.8% (n = 13) | 44.8% (n = 13) |
| Penile cancer | 0% (n = 0) | 0% (n = 0) | 0% (n = 0) | 17.5% (n = 11) | 25.4% (n = 16) |
| Prostate cancer | 0.02% (n = 1) | 0.2% (n = 4) | 0.4% (n = 8) | 4.2% (n = 239) | 5.4% (n = 312) |
| Renal cell carcinoma | 0% (n = 0) | 0.5% (n = 1) | 0% (n = 0) | 4.4% (n = 115) | 6.2% (n = 160) |
| Salivary gland cancer | 0.7% (n = 7) | 0.5% (n = 1) | 15.3% (n = 29) | 6.3% (n = 64) | 9.2% (n = 93) |
| Sex cord stromal tumor | 0% (n = 0)a | 0% (n = 0) | 0% (n = 0) | 3.8% (n = 9) | 4.6% (n = 11) |
| Skin cancer, nonmelanoma | 3.8% (n = 46) | 1.6% (n = 3) | 6.4% (n = 12) | 32.6% (n = 396) | 36.9% (n = 448) |
| Small bowel cancer | 2.6% (n = 12) | 0% (n = 0) | 0% (n = 0) | 26.7% (n = 124) | 35.3% (n = 164) |
| Small cell lung cancer | 0% (n = 0) | 0.7% (n = 1) | 0.7% (n = 1) | 16.3% (n = 151) | 35.8% (n = 332) |
| Soft tissue sarcoma | 0.3% (n = 16) | 0.3% (n = 4) | 2.3% (n = 34) | 4.1% (n = 202) | 5.8% (n = 287) |
| Thyroid cancer | 40.2% (n = 922) | 36% (n = 96) | 17.2% (n = 46) | 8.7% (n = 199) | 10.1% (n = 231) |
| Uterine sarcoma | 0.1% (n = 1) | 0.6% (n = 1) | 2.3% (n = 4) | 5.1% (n = 36) | 6% (n = 42) |
| Vaginal cancer | 0% (n = 0) | 0% (n = 0) | 0% (n = 0) | 11.4% (n = 19) | 21.6% (n = 36) |
| Vulvar carcinoma | 0% (n = 0)a | 0% (n = 0)a | 0% (n = 0)a | 0% (n = 0) | 33.3% (n = 1) |
| Wilms tumor | 2.1% (n = 4) | 0% (n = 0) | 0% (n = 0) | 4.7% (n = 9) | 4.7% (n = 9) |
Note: Additional cancer types are presented in Supplementary Table S2.
aIt is possible that gene might have not been profiled for this alteration.